NUTM1 and nut midline carcinoma: NUT midline carcinoma is diagnosed by immunohistochemistry with a NUT antibody (more than 50% positivity in tumor nuclei is considered to be diagnostic) or the demonstration of NUT rearrangements by fluorescence in situ hybridization (FISH), reverse-transcription PCR, cytogenetics, or next-generation sequencing [1].